News ANGLE plc

Equities

AGL

GB0034330679

Advanced Medical Equipment & Technology

Market Closed - London S.E. Other stock markets 16:35:20 13/06/2025 BST			5-day change	1st Jan Change
7.250 ^GBX	+3.57%		+3.57%	-29.27%

06-06	ANGLE plc Auditor Raises 'Going Concern' Doubt	CI
06-06	Angle plc Announces Board Changes	CI

ANGLE PLC - PARSORTIX SYSTEM enableS novel DISCOVERIES into the biology of cancer	06-11	AQ
ANGLE : Sustainability and ESG strategy overview 2024	06-10	PU
ANGLE plc Auditor Raises 'Going Concern' Doubt	06-06	CI
ANGLE : Annual Report December 2024	06-06	PU
Angle plc Announces Board Changes	06-06	CI
Angle Announces Reviewing Board Structure And Composition	06-06	RE
ANGLE plc - Preliminary Results for the year ended 31 December 2024	05-29	AQ
Stocks fall as trade optimism fades; Nvidia ahead	05-28	AN
ANGLE plc, 2024 Earnings Call, May 28, 2025	05-28
Angle shares fall on weak 2025 outlook despite narrower annual loss	05-28	AN
AIM WINNERS & LOSERS: Frontier Developments revenue to beat consensus	05-28	AN
RBC cuts National Grid; Citigroup cuts South32	05-28	AN
London green as grocery sales rise on warm weather	05-28	AN
Angle PLC Sees Cash Runway Into Q1 2026	05-28	RE
ANGLE plc Reports Earnings Results for the Full Year Ended December 31, 2024	05-28	CI
ANGLE plc Announces the Presentation of New Data for Angle's Her2-Ctc Assay At the American Association for Cancer Research Annual Meeting	04-28	CI
ANGLE plc - Issue of LTIP Options and Share Options	03-24	AQ
ANGLE PLC - UPDATE ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACT	03-24	AQ
Angle hails successful completion of Eisai contract; approval by Astra	03-21	AN
Angle's Breast Cancer Assay Shows Real-time Monitoring Promise in Mid-stage Pilot Study	03-21	MT
Angle- Results Of Eisai Phase 2 Pilot study supports applicability of Parsortix-Based HER2 Assay For Use In ADC Clinical Trials	03-21	RE
Angle reports breakthrough in dual cancer DNA analysis	01-29	AN
Angle plc Validates Tumor DNA Dual Analysis Workflow Results Using Illumina Inc Assay, Platform	01-29	MT
ANGLE PLC - CLINICAL TRIAL POWERED BY PARSORTIX SYSTEM PROVIDES FIRST-IN-CLASS data FOR NOVEL APPROACH TO CANCER treatment	01-27	AQ
Angle fails to win market confidence despite narrowing loss in 2024	01-23	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ANGLE plc

Equities

AGL

GB0034330679

Advanced Medical Equipment & Technology

Filters